Kwok-Man Lee, MD
Internal Medicine · New York, NYNPI 1538262464
Payments from drug & device makers
Across 1,033 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Boehringer Ingelheim$3K
- Novo Nordisk$2K
- GSK$2K
- Lilly USA, LLC$1K
- Amgen$1K
- plus $7K from 29 others
What the payments were for
- Food & beverage$22,88099%
- Education$2801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 305 | $7,177 |
| Boehringer Ingelheim | 106 | $2,846 |
| Novo Nordisk | 111 | $2,143 |
| GSK | 113 | $2,133 |
| Lilly USA, LLC | 53 | $1,116 |
| Amgen | 41 | $1,113 |
| Gilead | 35 | $888 |
| Merck | 29 | $718 |
| Johnson & Johnson | 33 | $625 |
| Sumitomo Pharma America, Inc. | 29 | $545 |
| Bayer | 18 | $449 |
| AbbVie(2 entities) | 20 | $411 |
| Amarin Pharma, Inc. | 22 | $404 |
| Esperion Therapeutics, Inc. | 13 | $279 |
| OPKO Pharmaceuticals, LLC | 11 | $277 |
| Pfizer | 10 | $263 |
| E.r. Squibb & Sons, L.L.C. | 12 | $243 |
| Astellas Pharma US Inc | 10 | $223 |
| Nestle Healthcare Nutrition Inc. | 9 | $203 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $199 |
| Xeris Pharmaceuticals, Inc. | 9 | $170 |
| Ironwood Pharmaceuticals, Inc | 7 | $130 |
| Exact Sciences | 4 | $122 |
| Kowa Pharmaceuticals America, Inc. | 4 | $99 |
| Biohaven Pharmaceuticals, Inc. | 3 | $73 |
| Seqirus USA Inc | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 3 | $47 |
| Vifor Pharma, Inc. | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| IBSA Pharma Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Argenx US, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,160 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 366 | $427,657 |
| VascepaIcosapent Ethyl | 402 | $275,496 |
| JardianceEmpagliflozin | 217 | $275,182 |
| RybelsusSemaglutide | 116 | $243,914 |
| ProliaDenosumab | 75 | $129,312 |
| OzempicSemaglutide | 77 | $123,786 |
| VemlidyTenofovir Alafenamide | 67 | $98,062 |
| Diclofenac Epolamine | 111 | $91,049 |
| TradjentaLinagliptin | 96 | $79,693 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $63,173 |
| XareltoRivaroxaban | 41 | $57,882 |
| EliquisApixaban | 46 | $54,748 |
| MounjaroTirzepatide | 39 | $46,160 |
| JanuviaSitagliptin Phosphate | 42 | $44,883 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $37,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $7,177 | $471,426439 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $2,846 | $368,892329 claims |
| Novo NordiskRybelsus, Ozempic | $2,143 | $367,699193 claims |
| AmgenProlia, Evenity (2 Syringes) | $1,113 | $154,73986 claims |
| GileadVemlidy | $888 | $98,06267 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,116 | $69,78358 claims |
| PfizerEliquis, Abrysvo | $263 | $68,49297 claims |
| GSKTrelegy Ellipta | $2,133 | $63,17376 claims |
| Johnson & JohnsonXarelto | $625 | $57,88241 claims |
| AbbVieLinzess, Namzaric, Synthroid | $411 | $57,816103 claims |
| MerckJanuvia, Janumet | $718 | $56,68854 claims |
| Astellas Pharma US IncMyrbetriq | $223 | $30,11432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.